Scope of treatment with Osimertinib
Osimertinib, as a third-generation EGFR-TKI targeted drug, covers the full course management of EGFR mutation positive non-small cell lung cancer (NSCLC), including adjuvant therapy, local advanced stage, and metastatic stage, with clear efficacy especially for T790M resistant mutation patients.
1. Adjuvant treatment stage
(1) Suitable for adult NSCLC patients with EGFR exon 19 deletion or exon 21 L858R mutation confirmed by postoperative testing, requiring continuous medication for 3 years or disease recurrence.
2. Local late stage treatment
(1) For stage III unresectable patients who have not progressed after platinum based radiotherapy and chemotherapy, it is required that the tumor has an EGFR sensitive mutation (19del/L858R).
3. Transfer therapy
(1) First line monotherapy: The standard treatment for EGFR sensitive metastatic NSCLC, continuing until disease progression.
(2) Combination therapy: Used in combination with pemetrexed and platinum based chemotherapy for first-line treatment of locally advanced/metastatic patients.
(3) Post resistance treatment: for metastatic patients who have failed EGFR-TKI treatment and developed T790M mutation.
4. Special population coverage
(1) Patients with renal insufficiency (CrCl ≥ 15mL/min) and mild liver damage do not require dose adjustment, but there is no recommended dose for end-stage renal disease and severe liver damage.
Disclaimer：《Scope of treatment with Osimertinib》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！